StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
PASG

Passage Bio, Inc.

PASG Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$4.49
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap
$14.4M
Revenue (TTM)
Net income (TTM)
-$37.7M
EPS (TTM)
$-11.84
P/E ratio
Dividend yield
Free cash flow
-$31.5M
Cash
$33.3M
Total assets
$36.5M
Gross margin
52-week range
$3.29 – $20.00

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Entered a material agreement; Terminated a material agreement; Unregistered sale of equity; Change in control; Director or officer change; Regulation FD disclosure; Other events Jun 24, 2026 8-K Terminated a material agreement May 27, 2026 8-K Shareholder vote results May 26, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Exit or disposal costs Apr 28, 2026 8-K Regulation FD disclosure Apr 20, 2026 8-K Terminated a material agreement Mar 10, 2026 10-K Fiscal year ended 2025-12-31 Mar 3, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 3, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Jan 12, 2026 10-Q Quarter ended 2025-09-30 Nov 10, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 10, 2025 8-K Director or officer change Sep 18, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Aug 12, 2025 8-K Other events Jul 29, 2025 8-K Modified rights of security holders; Amended charter or bylaws; Other events Jul 14, 2025 8-K Other events Jun 23, 2025 8-K Shareholder vote results May 30, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 13, 2025 10-K Fiscal year ended 2024-12-31 Mar 4, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 4, 2025 8-K Delisting notice or listing-rule failure Jan 31, 2025 8-K Results of operations (earnings release); Exit or disposal costs; Material impairment; Regulation FD disclosure; Other events Jan 10, 2025 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Nov 13, 2024 8-K Regulation FD disclosure Oct 24, 2024 8-K Regulation FD disclosure; Other events Sep 16, 2024 8-K Director or officer change Sep 10, 2024 8-K Material impairment Sep 6, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Aug 8, 2024 8-K Delisting notice or listing-rule failure Aug 2, 2024 8-K Entered a material agreement; Results of operations (earnings release); Director or officer change; Regulation FD disclosure Aug 1, 2024 8-K Regulation FD disclosure; Other events Jul 16, 2024 8-K Shareholder vote results May 22, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2024 10-K Fiscal year ended 2023-12-31 Mar 4, 2024